Similar articles

• Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.

  Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P. Vaghi F, et al. Drugs Exp Clin Res. 1993;19(6):249-60. Drugs Exp Clin Res. 1993. PMID: 8013268
• A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.

  Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O, Patrono C. Salvati P, et al. J Pharmacol Exp Ther. 1994 Apr;269(1):238-45. J Pharmacol Exp Ther. 1994. PMID: 8169831
• Thromboxane receptors antagonists and/or synthase inhibitors.

  Davì G, Santilli F, Vazzana N. Davì G, et al. Handb Exp Pharmacol. 2012;(210):261-86. doi: 10.1007/978-3-642-29423-5_11. Handb Exp Pharmacol. 2012. PMID: 22918735 Review.
• R68070, a combined thromboxane/endoperoxide receptor antagonist (TRA) and thromboxane synthase inhibitor (TSI), prolongs the bleeding time more than aspirin in man.

  Hoet B, Arnout J, Vermylen J. Hoet B, et al. Prog Clin Biol Res. 1989;301:573-7. Prog Clin Biol Res. 1989. PMID: 2552467 Clinical Trial. No abstract available.
• The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists.

  Radomski M. Radomski M. Acta Physiol Pol. 1985 May-Jun;36(3):153-64. Acta Physiol Pol. 1985. PMID: 3915630 Review.